Biologics and Biosimilars: Background and Key Issues
Full report
What this is
The Congressional Research Service is a nonpartisan policy and legal analysis arm of the Library of Congress. CRS reports are written for members of Congress and their staff, not the public — but they’re made available openly through Congress.gov.
- HR 2430115th Congress
FDA Reauthorization Act of 2017
Aug 18, 2017 · Signed by President.
- HR 6115th Congress
SUPPORT for Patients and Communities Act
Oct 24, 2018 · Became Public Law No: 115-271.
- S 2554115th Congress
Patient Right to Know Drug Prices Act
Oct 10, 2018 · Became Public Law No: 115-263.
- HR 5126116th Congress
DESCEND Act of 2020
Jan 13, 2021 · Became Public Law No: 116-340.
- HR 965116th Congress
CREATES Act of 2019
May 16, 2019 · Supplemental report filed by the Committee on the Judiciary, H. Rept. 116-55, Part III.
- S 340116th Congress
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Feb 6, 2019 · Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
- S 659116th Congress
Biologic Patent Transparency Act
Mar 5, 2019 · Read twice and referred to the Committee on Health, Education, Labor, and Pensions.